|
|
Volumn 19, Issue 12, 2013, Pages 1550-1550
|
|
Kinesin inhibitor marches toward first-in-class pivotal trial
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
ARRY 520;
KIF11 PROTEIN, HUMAN;
KINESIN;
PHARMACOLOGICAL BIOMARKER;
THIADIAZOLE DERIVATIVE;
TUBULIN MODULATOR;
CLINICAL TRIAL (TOPIC);
DRUG ANTAGONISM;
HUMAN;
METHODOLOGY;
MOLECULARLY TARGETED THERAPY;
NEOPLASM;
NOTE;
PHYSIOLOGY;
PILOT STUDY;
ANTAGONISTS AND INHIBITORS;
NEOPLASMS;
PROCEDURES;
ANTINEOPLASTIC AGENTS;
BIOMARKERS, PHARMACOLOGICAL;
CLINICAL TRIALS AS TOPIC;
HUMANS;
KINESIN;
MOLECULAR TARGETED THERAPY;
NEOPLASMS;
PILOT PROJECTS;
THIADIAZOLES;
TUBULIN MODULATORS;
|
|
EID: 84894633297
PISSN: 10788956
EISSN: 1546170X
Source Type: Journal
DOI: 10.1038/nm1213-1550a Document Type: Article |
|
Times cited : (25)
|
|
References (0)
|